Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Buy” from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has been assigned an average rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $59.22.

A number of brokerages have recently weighed in on VERA. Guggenheim boosted their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. raised their target price on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th.

Vera Therapeutics Trading Up 1.9 %

Vera Therapeutics stock opened at $49.75 on Monday. Vera Therapeutics has a 12 month low of $13.07 and a 12 month high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a market cap of $3.15 billion, a P/E ratio of -19.06 and a beta of 1.03. The company’s fifty day simple moving average is $44.21 and its 200-day simple moving average is $39.77.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). As a group, sell-side analysts forecast that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of Vera Therapeutics stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total transaction of $49,445.77. Following the transaction, the director now directly owns 160,376 shares in the company, valued at approximately $6,737,395.76. The trade was a 0.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marshall Fordyce sold 23,125 shares of the business’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25. Following the completion of the transaction, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $14,182,110.60. The trade was a 6.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 89,927 shares of company stock worth $3,800,796 in the last ninety days. Company insiders own 21.70% of the company’s stock.

Institutional Trading of Vera Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of Vera Therapeutics by 31.5% in the first quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock valued at $92,653,000 after buying an additional 515,106 shares during the period. Holocene Advisors LP boosted its stake in Vera Therapeutics by 8.8% in the 3rd quarter. Holocene Advisors LP now owns 1,954,528 shares of the company’s stock worth $86,390,000 after purchasing an additional 158,451 shares during the period. Samlyn Capital LLC increased its holdings in Vera Therapeutics by 90.8% during the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock worth $44,571,000 after purchasing an additional 586,410 shares in the last quarter. First Light Asset Management LLC raised its stake in shares of Vera Therapeutics by 130.6% in the 2nd quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after purchasing an additional 569,590 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Vera Therapeutics by 2.1% in the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock valued at $44,415,000 after purchasing an additional 20,223 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.